APP Pharmaceuticals Receives Approval For Chlorothiazide Sodium For Injection
APP Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. Chlorothiazide Sodium for Injection, USP is therapeutically equivalent to the reference-listed drug Diuril®, which is marketed by Lundbeck Pharmaceuticals. Chlorothiazide is a diuretic used to treat high blood pressure, and fluid retention in people with congestive heart failure, cirrhosis of the liver and kidney disorders.
- Opto Circuits receives FDA nod to sell vital signs monitoring devices in US
- Angiotech receives clearance for new sizes of Quill SRS PDO
- The first “suitcase” ICU receives CE approval
- Nano Mask moving ahead to get FDA approval for NanoMask
